Royalty Gross Profit from 2010 to 2025

RPRX Stock

USD 33.38 0.31 0.92%

Royalty Pharma Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 1.5 B in 2025. Gross Profit is the profit Royalty Pharma Plc makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2016-12-31

Previous Quarter

563 M

Current Value

594 M

Quarterly Volatility

208.7 M

Covid

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.

Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Royalty Pharma Plc over the last few years. Gross profit is a required income statement account that reflects total revenue of Royalty Pharma Plc minus its cost of goods sold. It is profit before Royalty Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Royalty Pharma's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.53 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Royalty Gross Profit Regression Statistics

	Arithmetic Mean	1,006,609,725
	Geometric Mean	0.00
	Coefficient Of Variation	97.56
	Mean Deviation	907,243,100
	Median	1,464,159,600
	Standard Deviation	982,040,398
	Sample Variance	964403.3T
	Range	2.3B
	R-Value	0.85
	Mean Square Error	280868T
	R-Squared	0.73
	Significance	0.000026
	Slope	176,017,197
	Total Sum of Squares	14466050.1T

Royalty Gross Profit History

	2025	1.5 B
	2024	2.3 B
	2023	1.8 B
	2022	2.2 B
	2021	2.3 B
	2020	2 B
	2019	794.9 M

Other Fundumenentals of Royalty Pharma Plc

Gross Profit Margin

Royalty Pharma Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Net Debt	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue	Capital Surpluse
Total Assets		0.96	0.84	0.19	0.96	-0.23	0.16	-0.37	-0.23	0.93	0.92	0.86	0.71	0.24	0.05	0.28	0.66	0.86	0.82	-0.85	-0.4	0.42	-0.42	0.67
Total Stockholder Equity	0.96		0.9	0.01	0.91	-0.23	0.12	-0.34	-0.25	0.86	0.88	0.74	0.78	0.25	-0.11	0.33	0.71	0.85	0.77	-0.81	-0.55	0.3	-0.6	0.68
Accounts Payable	0.84	0.9		-0.24	0.78	-0.2	0.03	-0.27	-0.36	0.78	0.86	0.48	0.84	0.12	0.12	0.2	0.75	0.87	0.73	-0.77	-0.73	0.16	-0.56	0.71
Short Term Investments	0.19	0.01	-0.24		0.11	0.32	0.03	-0.34	0.15	0.18	0.11	0.42	-0.21	0.03	-0.16	-0.05	-0.23	0.01	0.17	-0.14	0.6	0.51	0.44	-0.22
Total Liab	0.96	0.91	0.78	0.11		-0.33	0.37	-0.38	-0.12	0.95	0.92	0.89	0.71	0.29	0.05	0.33	0.68	0.77	0.68	-0.72	-0.46	0.4	-0.43	0.64
Treasury Stock	-0.23	-0.23	-0.2	0.32	-0.33		-0.42	-0.68	0.09	-0.31	-0.28	-0.26	-0.18	-0.03	0.06	-0.04	-0.15	-0.08	0.01	0.01	0.22	0.0	0.1	-0.07
Common Stock	0.16	0.12	0.03	0.03	0.37	-0.42		-0.16	0.54	0.37	0.28	0.34	-0.03	-0.24	-0.16	-0.25	-0.14	-0.24	-0.36	0.37	-0.14	-0.2	0.17	-0.31
Property Plant Equipment	-0.37	-0.34	-0.27	-0.34	-0.38	-0.68	-0.16		-0.27	-0.37	-0.36	-0.34	-0.25	-0.07	-0.03	-0.08	-0.23	-0.28	-0.26	0.26	0.16	-0.14	0.12	-0.22
Intangible Assets	-0.23	-0.25	-0.36	0.15	-0.12	0.09	0.54	-0.27		-0.13	-0.2	-0.01	-0.4	-0.32	-0.13	-0.34	-0.45	-0.5	-0.49	0.51	0.21	-0.32	0.31	-0.51
Net Tangible Assets	0.93	0.86	0.78	0.18	0.95	-0.31	0.37	-0.37	-0.13		0.98	0.83	0.73	0.15	0.12	0.23	0.66	0.79	0.72	-0.7	-0.45	0.39	-0.22	0.63
Retained Earnings	0.92	0.88	0.86	0.11	0.92	-0.28	0.28	-0.36	-0.2	0.98		0.74	0.82	0.16	0.08	0.25	0.73	0.85	0.75	-0.73	-0.54	0.39	-0.29	0.67
Total Current Assets	0.86	0.74	0.48	0.42	0.89	-0.26	0.34	-0.34	-0.01	0.83	0.74		0.37	0.22	0.05	0.23	0.37	0.57	0.63	-0.64	-0.02	0.45	-0.15	0.43
Net Debt	0.71	0.78	0.84	-0.21	0.71	-0.18	-0.03	-0.25	-0.4	0.73	0.82	0.37		0.43	-0.05	0.55	0.96	0.88	0.69	-0.7	-0.79	0.38	-0.63	0.85
Long Term Debt	0.24	0.25	0.12	0.03	0.29	-0.03	-0.24	-0.07	-0.32	0.15	0.16	0.22	0.43		-0.3	0.96	0.59	0.38	0.3	-0.37	-0.07	0.78	-0.59	0.54
Net Receivables	0.05	-0.11	0.12	-0.16	0.05	0.06	-0.16	-0.03	-0.13	0.12	0.08	0.05	-0.05	-0.3		-0.34	0.04	0.16	0.24	-0.21	-0.07	-0.12	0.32	0.23
Long Term Debt Total	0.28	0.33	0.2	-0.05	0.33	-0.04	-0.25	-0.08	-0.34	0.23	0.25	0.23	0.55	0.96	-0.34		0.69	0.47	0.39	-0.42	-0.18	0.7	-0.62	0.66
Net Invested Capital	0.66	0.71	0.75	-0.23	0.68	-0.15	-0.14	-0.23	-0.45	0.66	0.73	0.37	0.96	0.59	0.04	0.69		0.87	0.71	-0.72	-0.73	0.47	-0.67	0.94
Long Term Investments	0.86	0.85	0.87	0.01	0.77	-0.08	-0.24	-0.28	-0.5	0.79	0.85	0.57	0.88	0.38	0.16	0.47	0.87		0.94	-0.95	-0.54	0.5	-0.51	0.9
Short Long Term Debt	0.82	0.77	0.73	0.17	0.68	0.01	-0.36	-0.26	-0.49	0.72	0.75	0.63	0.69	0.3	0.24	0.39	0.71	0.94		-0.97	-0.27	0.5	-0.32	0.83
Capital Stock	-0.85	-0.81	-0.77	-0.14	-0.72	0.01	0.37	0.26	0.51	-0.7	-0.73	-0.64	-0.7	-0.37	-0.21	-0.42	-0.72	-0.95	-0.97		0.31	-0.53	0.46	-0.83
Net Working Capital	-0.4	-0.55	-0.73	0.6	-0.46	0.22	-0.14	0.16	0.21	-0.45	-0.54	-0.02	-0.79	-0.07	-0.07	-0.18	-0.73	-0.54	-0.27	0.31		0.18	0.63	-0.58
Short Term Debt	0.42	0.3	0.16	0.51	0.4	0.0	-0.2	-0.14	-0.32	0.39	0.39	0.45	0.38	0.78	-0.12	0.7	0.47	0.5	0.5	-0.53	0.18		-0.14	0.45
Current Deferred Revenue	-0.42	-0.6	-0.56	0.44	-0.43	0.1	0.17	0.12	0.31	-0.22	-0.29	-0.15	-0.63	-0.59	0.32	-0.62	-0.67	-0.51	-0.32	0.46	0.63	-0.14		-0.59
Capital Surpluse	0.67	0.68	0.71	-0.22	0.64	-0.07	-0.31	-0.22	-0.51	0.63	0.67	0.43	0.85	0.54	0.23	0.66	0.94	0.9	0.83	-0.83	-0.58	0.45	-0.59

Click cells to compare fundamentals

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	2.3 B	1.5 B
Gross Profit Margin	0.76	0.69

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC